Scholar iON
Academic Synthesis
The paper by Liu and Salmon (2024) articulates the pressing need for enhanced vaccine strategies against Dengue virus (DENV), given the limitations of the current FDA-approved vaccine, Dengvaxia, which poses risks like antibody-dependent enhancement (ADE). The authors highlight the emergence of mRNA technologies as promising alternatives, reflecting on their potential to overcome challenges associated with existing vaccines. The recent pre-approval of TAK-003 by WHO underscores the momentum in dengue vaccine innovation, but the synthesis identifies mRNA-based vaccines as pivotal in addressing ongoing issues, such as enhancing efficacy and safety in diverse demographic groups. This research contributes significantly to the discourse on global dengue prevention strategies by advocating for the integration of cutting-edge mRNA technologies in vaccine development.
Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.